Identification

Name
Oxaprozin
Accession Number
DB00991  (APRD00030)
Type
Small Molecule
Groups
Approved
Description

Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.

Structure
Thumb
Synonyms
  • Danoprox
  • Dayrun
  • Deflam
  • Duraprox
  • Oxaprozina
  • Oxaprozine
  • Oxaprozinum
  • Walix
External IDs
WY-21,743
Product Ingredients
IngredientUNIICASInChI Key
Oxaprozin potassiumML56O2Z92I174064-08-5QTAQWNSMRSLSCG-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DayproTablet600 mgOralPfizer1997-01-072012-09-20Canada
DayproTablet, film coated600 mg/1OralG.D. Searle LLC Division of Pfizer Inc1992-10-29Not applicableUs00025 1381 31 nlmimage10 811340aa
DayproTablet, film coated600 mg/1OralPd Rx Pharmaceuticals, Inc.1992-10-29Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-oxaprozinTablet600 mgOralApotex Corporation2001-05-29Not applicableCanada
OxaprozinTablet, film coated600 mg/1OralRebel Distributors2010-09-08Not applicableUs
OxaprozinTablet600 mg/1OralAv Kare, Inc.2014-03-06Not applicableUs
OxaprozinTablet, film coated600 mg/1OralGreenstone, Llc2013-03-27Not applicableUs59762 6002 01 nlmimage10 f43c7a03
OxaprozinTablet, film coated600 mg/1OralClinical Solutions Wholsesale2001-01-312017-06-24Us55111 0170 05 nlmimage10 58052c19
OxaprozinTablet, film coated600 mg/1OralPd Rx Pharmaceuticals, Inc.2003-05-12Not applicableUs
OxaprozinTablet600 mg/1OralDispensing Solutions, Inc.2001-01-31Not applicableUs
OxaprozinTablet, film coated600 mg/1Oralbryant ranch prepack2003-05-12Not applicableUs
OxaprozinTablet, film coated600 mg/1OralA S Medication Solutions2001-01-312017-06-20Us
OxaprozinTablet, film coated600 mg/1OralTeva2003-05-12Not applicableUs
International/Other Brands
Alvo / Daypro / Daypro Alta
Categories
UNII
MHJ80W9LRB
CAS number
21256-18-8
Weight
Average: 293.3166
Monoisotopic: 293.105193351
Chemical Formula
C18H15NO3
InChI Key
OFPXSFXSNFPTHF-UHFFFAOYSA-N
InChI
InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)
IUPAC Name
3-(diphenyl-1,3-oxazol-2-yl)propanoic acid
SMILES
OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

Used to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis.

Associated Conditions
Pharmacodynamics

Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Oxaprozin is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain.

Mechanism of action

Anti-inflammatory effects of Oxaprozin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Oxaprozin is a non-selective NSAID, with a cell assay system showing lower COX-2 selectivity implying higher COX-1 selectivity.

TargetActionsOrganism
AProstaglandin G/H synthase 1
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
Absorption

Oxaprozin is 95% absorbed after oral administration. Food may reduce the rate of absorption of oxaprozin, but the extent of absorption is unchanged. Antacids do not significantly affect the extent and rate of oxaprozin absorption.

Volume of distribution
  • 11 to 17 L/70 kg
Protein binding

>99.5% bound to albumin

Metabolism

Hepatic. Ester and ether glucuronide are the major conjugated metabolites of oxaprozin, and do not have significant pharmacologic activity.

Route of elimination

Oxaprozin is expected to be excreted in human milk based on its physical-chemical properties; however, the amount of oxaprozin excreted in breast milk has not been evaluated. Approximately 95% of oxaprozin is metabolized by the liver. Approximately 5% of the oxaprozin dose is excreted unchanged in the urine. Sixty-five percent (65%) of the dose is excreted in the urine and 35% in the feces as metabolite. Biliary excretion of unchanged oxaprozin is a minor pathway. Several oxaprozin metabolites have been identified in human urine or feces.

Half life

54.9 hours

Clearance
Not Available
Toxicity

Oral, mouse: LD50 = 1210 mg/kg; Oral, rabbit: LD50 = 172 mg/kg; Oral, rat: LD50 = 4470 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Oxaprozin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Oxaprozin.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with 5-androstenedione.Experimental, Illicit
AbciximabOxaprozin may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Oxaprozin can be decreased when combined with Abiraterone.Approved
AcebutololOxaprozin may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolOxaprozin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Acetaminophen.Approved
Acetyl sulfisoxazoleThe metabolism of Oxaprozin can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Oxaprozin.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Oxaprozin.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Oxaprozin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Alendronic acid.Approved
AliskirenOxaprozin may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Oxaprozin.Experimental
AlprenololOxaprozin may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Oxaprozin.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Amcinonide.Approved
AmikacinOxaprozin may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideOxaprozin may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Oxaprozin can be decreased when combined with Amiodarone.Approved, Investigational
AncrodOxaprozin may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Oxaprozin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Oxaprozin.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Antipyrine.Approved, Investigational
Antithrombin III humanOxaprozin may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Oxaprozin can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanOxaprozin may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Oxaprozin.Investigational
ApramycinOxaprozin may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Oxaprozin.Approved, Investigational
AprepitantThe metabolism of Oxaprozin can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinOxaprozin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinOxaprozin may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanOxaprozin may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololOxaprozin may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineOxaprozin may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Atamestane.Investigational
AtenololOxaprozin may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Oxaprozin.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxaprozin.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxaprozin.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Oxaprozin.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Balsalazide.Approved, Investigational
BazedoxifeneOxaprozin may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminOxaprozin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololOxaprozin may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinOxaprozin may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Oxaprozin.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxaprozin.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Oxaprozin.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Oxaprozin.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Oxaprozin.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Oxaprozin.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Oxaprozin.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Betamethasone.Approved, Vet Approved
BetaxololOxaprozin may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Oxaprozin.Approved, Investigational
BevantololOxaprozin may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Oxaprozin.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Oxaprozin.Approved, Investigational
BisoprololOxaprozin may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinOxaprozin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololOxaprozin may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Oxaprozin.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Oxaprozin.Investigational
BucindololOxaprozin may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Bufexamac.Approved, Experimental
BufuralolOxaprozin may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Oxaprozin.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Oxaprozin.Approved
BupranololOxaprozin may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Oxaprozin.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Oxaprozin.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Oxaprozin can be decreased when combined with Capecitabine.Approved, Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Captopril.Approved
CarbamazepineThe metabolism of Oxaprozin can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Oxaprozin.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Oxaprozin.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Oxaprozin.Approved, Vet Approved, Withdrawn
CarteololOxaprozin may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolOxaprozin may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Oxaprozin.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Oxaprozin.Approved, Investigational
CeliprololOxaprozin may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Oxaprozin can be increased when it is combined with Ceritinib.Approved
CertoparinOxaprozin may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Oxaprozin.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxaprozin.Approved, Vet Approved
ChlorotrianiseneOxaprozin may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Oxaprozin.Approved
CholecalciferolThe metabolism of Oxaprozin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Cimicoxib.Investigational
CinoxacinOxaprozin may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinOxaprozin may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Cisplatin.Approved
CitalopramCitalopram may increase the antiplatelet activities of Oxaprozin.Approved
Citric AcidOxaprozin may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Oxaprozin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Oxaprozin.Vet Approved
CloranololOxaprozin may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneOxaprozin may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Oxaprozin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensOxaprozin may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Oxaprozin can be decreased when combined with Crisaborole.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Oxaprozin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Oxaprozin.Experimental
CyclosporineOxaprozin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateOxaprozin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Oxaprozin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaidzeinOxaprozin may increase the thrombogenic activities of Daidzein.Experimental
DalteparinOxaprozin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidOxaprozin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Oxaprozin.Investigational
DarexabanOxaprozin may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Delapril.Experimental
DelavirdineThe metabolism of Oxaprozin can be decreased when combined with Delavirdine.Approved
DesipramineOxaprozin may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinOxaprozin may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Oxaprozin.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Oxaprozin.Approved, Investigational
DextranOxaprozin may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinOxaprozin may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Oxaprozin.Approved, Vet Approved
DicoumarolOxaprozin may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolOxaprozin may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolOxaprozin may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Oxaprozin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Oxaprozin.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Oxaprozin.Approved
DihydrostreptomycinOxaprozin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Oxaprozin.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Oxaprozin.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Oxaprozin.Approved
DiphenadioneOxaprozin may increase the anticoagulant activities of Diphenadione.Experimental
DosulepinThe metabolism of Oxaprozin can be decreased when combined with Dosulepin.Approved
DrospirenoneOxaprozin may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Oxaprozin.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Oxaprozin.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Oxaprozin.Investigational
Edetic AcidOxaprozin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanOxaprozin may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Oxaprozin can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Enalaprilat.Approved
EnoxacinOxaprozin may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinOxaprozin may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Oxaprozin.Experimental
EpanololOxaprozin may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolOxaprozin may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Oxaprozin.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Oxaprozin.Experimental
EplerenoneOxaprozin may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Oxaprozin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Oxaprozin.Approved
EquileninThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Equilin.Approved
EquolOxaprozin may increase the thrombogenic activities of Equol.Investigational
EsatenololOxaprozin may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Oxaprozin.Approved, Investigational
EsmololOxaprozin may decrease the antihypertensive activities of Esmolol.Approved
EstradiolOxaprozin may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateOxaprozin may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateOxaprozin may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateOxaprozin may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolOxaprozin may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedOxaprozin may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxaprozin.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Oxaprozin.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Oxaprozin.Experimental
Ethinyl EstradiolOxaprozin may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateOxaprozin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Oxaprozin.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Oxaprozin.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Oxaprozin.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Oxaprozin can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Oxaprozin.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Oxaprozin.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Oxaprozin.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Oxaprozin.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Oxaprozin.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Oxaprozin.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Oxaprozin.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Oxaprozin.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Oxaprozin.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Oxaprozin.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fish oil.Approved, Nutraceutical
FleroxacinOxaprozin may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Oxaprozin.Approved, Withdrawn
FloxuridineThe metabolism of Oxaprozin can be decreased when combined with Floxuridine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Oxaprozin can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fludrocortisone.Approved, Investigational
FluindioneOxaprozin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineOxaprozin may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Oxaprozin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Oxaprozin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluorometholone.Approved, Investigational
FluorouracilThe metabolism of Oxaprozin can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Oxaprozin.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Oxaprozin.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Oxaprozin.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Oxaprozin can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Oxaprozin can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Oxaprozin.Approved, Nutraceutical, Vet Approved
FondaparinuxOxaprozin may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumOxaprozin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Oxaprozin.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Oxaprozin can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinOxaprozin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Oxaprozin.Approved, Vet Approved
GabexateOxaprozin may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinOxaprozin may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinOxaprozin may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Oxaprozin.Approved, Withdrawn
GemfibrozilThe metabolism of Oxaprozin can be decreased when combined with Gemfibrozil.Approved
GemifloxacinOxaprozin may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinOxaprozin may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinOxaprozin may increase the thrombogenic activities of Genistein.Investigational
GentamicinOxaprozin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AOxaprozin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinOxaprozin may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Oxaprozin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Oxaprozin is combined with HE3286.Investigational
HeparinOxaprozin may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolOxaprozin may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Oxaprozin.Investigational
HydralazineOxaprozin may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxaprozin.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Oxaprozin.Approved, Investigational
Hygromycin BOxaprozin may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Oxaprozin.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Oxaprozin.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Icosapent.Approved, Nutraceutical
IdraparinuxOxaprozin may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Oxaprozin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Oxaprozin.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Oxaprozin.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Oxaprozin.Approved
IndenololOxaprozin may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Oxaprozin can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Oxaprozin.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Oxaprozin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Oxaprozin.Withdrawn
IrbesartanThe metabolism of Oxaprozin can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinOxaprozin may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Oxaprozin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Istaroxime.Investigational
KanamycinOxaprozin may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Oxaprozin.Experimental
KetoconazoleThe metabolism of Oxaprozin can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Oxaprozin.Approved
LabetalolOxaprozin may decrease the antihypertensive activities of Labetalol.Approved
LandiololOxaprozin may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Oxaprozin.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Oxaprozin.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Oxaprozin.Approved, Investigational
LepirudinOxaprozin may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanOxaprozin may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololOxaprozin may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololOxaprozin may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinOxaprozin may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Oxaprozin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Oxaprozin.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Oxaprozin.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Oxaprozin.Approved
LobeglitazoneThe metabolism of Oxaprozin can be decreased when combined with Lobeglitazone.Approved, Investigational
LomefloxacinOxaprozin may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Oxaprozin.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Lornoxicam.Approved, Investigational
LosartanThe metabolism of Oxaprozin can be decreased when combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Loteprednol.Approved
LovastatinThe metabolism of Oxaprozin can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Oxaprozin.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Oxaprozin.Approved, Investigational
LumacaftorThe serum concentration of Oxaprozin can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Oxaprozin.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Magnesium salicylate.Approved
ManidipineThe metabolism of Oxaprozin can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Oxaprozin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Oxaprozin is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxaprozin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Oxaprozin.Approved
MelagatranOxaprozin may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Oxaprozin.Approved, Vet Approved
MepindololOxaprozin may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Oxaprozin.Approved
MestranolOxaprozin may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Oxaprozin.Approved, Investigational, Withdrawn
MethallenestrilOxaprozin may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Oxaprozin.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxaprozin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Methylprednisolone.Approved, Vet Approved
MetipranololOxaprozin may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Oxaprozin.Approved
MetoprololOxaprozin may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinOxaprozin may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Oxaprozin can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Oxaprozin.Approved, Experimental
MifepristoneThe serum concentration of Oxaprozin can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Oxaprozin.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Oxaprozin.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Oxaprozin.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Oxaprozin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Oxaprozin.Approved
MoxestrolOxaprozin may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinOxaprozin may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oxaprozin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oxaprozin.Approved
NabiloneThe metabolism of Oxaprozin can be decreased when combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Oxaprozin.Approved
NadololOxaprozin may decrease the antihypertensive activities of Nadolol.Approved
NadroparinOxaprozin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Oxaprozin.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Oxaprozin.Approved
Nalidixic AcidOxaprozin may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Oxaprozin.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Oxaprozin is combined with NCX 1022.Investigational
NeamineOxaprozin may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololOxaprozin may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Oxaprozin.Approved, Withdrawn
NemonoxacinOxaprozin may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinOxaprozin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Oxaprozin.Approved, Investigational
NetilmicinOxaprozin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe metabolism of Oxaprozin can be decreased when combined with Nicardipine.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Oxaprozin.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Oxaprozin.Investigational
NorfloxacinOxaprozin may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinOxaprozin may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Oxaprozin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxaprozin.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Oxaprozin.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Oxaprozin is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Oxaprozin can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Oxaprozin.Vet Approved
OtamixabanOxaprozin may increase the anticoagulant activities of Otamixaban.Investigational
Oxolinic acidOxaprozin may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololOxaprozin may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Oxaprozin.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Oxaprozin.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Parecoxib.Approved
ParomomycinOxaprozin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Oxaprozin.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Oxaprozin.Approved, Investigational
PazufloxacinOxaprozin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinOxaprozin may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololOxaprozin may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateOxaprozin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateOxaprozin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Perindopril.Approved
PhenindioneOxaprozin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Oxaprozin can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonOxaprozin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Oxaprozin.Approved, Vet Approved
PhenytoinThe metabolism of Oxaprozin can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaprozin.Approved, Investigational
PindololOxaprozin may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidOxaprozin may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Oxaprozin.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Oxaprozin.Approved, Investigational
Piromidic acidOxaprozin may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oxaprozin.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Oxaprozin.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorOxaprozin may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinOxaprozin may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
Polyestradiol phosphateOxaprozin may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Oxaprozin.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pomalidomide.Approved
Potassium CitrateOxaprozin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololOxaprozin may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Oxaprozin.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Oxaprozin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe metabolism of Oxaprozin can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Oxaprozin can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Oxaprozin.Experimental
PromestrieneOxaprozin may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Oxaprozin.Approved, Investigational
PropafenoneOxaprozin may decrease the antihypertensive activities of Propafenone.Approved
PropranololOxaprozin may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Oxaprozin.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Oxaprozin.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Oxaprozin.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Oxaprozin.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Oxaprozin.Vet Approved
Protein COxaprozin may increase the anticoagulant activities of Protein C.Approved
Protein S humanOxaprozin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeOxaprozin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinOxaprozin may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Oxaprozin.Investigational
PuromycinOxaprozin may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Oxaprozin can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Quinapril.Approved, Investigational
QuinestrolOxaprozin may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Oxaprozin.Approved
QuinineThe metabolism of Oxaprozin can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinOxaprozin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinOxaprozin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifampicinThe metabolism of Oxaprozin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Oxaprozin can be increased when combined with Rifapentine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Risedronate.Approved, Investigational
RivaroxabanOxaprozin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Oxaprozin.Approved, Investigational, Withdrawn
RosoxacinOxaprozin may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe metabolism of Oxaprozin can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinOxaprozin may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Oxaprozin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Oxaprozin.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Oxaprozin.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Oxaprozin.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Oxaprozin.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Oxaprozin.Approved, Investigational
SecobarbitalThe metabolism of Oxaprozin can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolOxaprozin may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Oxaprozin.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Oxaprozin.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Oxaprozin.Investigational
SertralineSertraline may increase the antiplatelet activities of Oxaprozin.Approved
SildenafilThe metabolism of Oxaprozin can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinOxaprozin may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinOxaprozin may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateOxaprozin may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Oxaprozin.Approved
SorafenibThe metabolism of Oxaprozin can be decreased when combined with Sorafenib.Approved, Investigational
SotalolOxaprozin may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinOxaprozin may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Spirapril.Approved
SpironolactoneOxaprozin may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Oxaprozin.Investigational
StreptomycinOxaprozin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfadiazineThe metabolism of Oxaprozin can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Oxaprozin can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Oxaprozin.Approved
SulfisoxazoleThe metabolism of Oxaprozin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Oxaprozin.Approved, Investigational
SulodexideOxaprozin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Oxaprozin.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Oxaprozin.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Oxaprozin.Experimental
Synthetic Conjugated Estrogens, AOxaprozin may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BOxaprozin may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusOxaprozin may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Oxaprozin.Approved
TalinololOxaprozin may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Oxaprozin.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Oxaprozin.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Oxaprozin.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Oxaprozin.Approved, Investigational
TemafloxacinOxaprozin may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Oxaprozin.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Oxaprozin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Oxaprozin.Vet Approved
TerbutalineOxaprozin may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Oxaprozin.Approved
TertatololOxaprozin may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tiaprofenic acid.Approved
TiboloneOxaprozin may increase the thrombogenic activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Oxaprozin can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Oxaprozin can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololOxaprozin may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Oxaprozin.Investigational
TioclomarolOxaprozin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tixocortol.Approved, Withdrawn
TobramycinOxaprozin may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Oxaprozin can be decreased when combined with Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Oxaprozin.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Oxaprozin.Approved
TopiroxostatThe metabolism of Oxaprozin can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Oxaprozin.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Oxaprozin.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Oxaprozin.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Oxaprozin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Triamcinolone.Approved, Vet Approved
TriamtereneOxaprozin may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Oxaprozin.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxaprozin.Approved, Vet Approved
TrimethoprimThe metabolism of Oxaprozin can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Oxaprozin.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Trolamine salicylate.Approved
TrovafloxacinOxaprozin may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinOxaprozin may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Oxaprozin.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Oxaprozin.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Oxaprozin can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Oxaprozin can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Oxaprozin.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Oxaprozin.Approved
VoriconazoleThe metabolism of Oxaprozin can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinOxaprozin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranOxaprozin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Oxaprozin can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Oxaprozin.Approved, Investigational
ZeranolOxaprozin may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Oxaprozin.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Oxaprozin.Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Oxaprozin.Withdrawn
Food Interactions
  • Take with food, usually once a day after breakfast. Food decreases the rate of absorption but not the amount absorbed. Avoid alcohol.

References

Synthesis Reference

Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. Pubmed.

General References
  1. Heller B, Tarricone R: Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder. Curr Med Res Opin. 2004 Aug;20(8):1279-90. [PubMed:15324531]
External Links
Human Metabolome Database
HMDB0015126
KEGG Drug
D00463
KEGG Compound
C07356
PubChem Compound
4614
PubChem Substance
46506429
ChemSpider
4453
BindingDB
50002861
ChEBI
7822
ChEMBL
CHEMBL1071
Therapeutic Targets Database
DAP000622
PharmGKB
PA450730
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Oxaprozin
ATC Codes
M01AE12 — Oxaprozin
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
FDA label
Download (47 KB)
MSDS
Download (63.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1

Pharmacoeconomics

Manufacturers
  • Gd searle llc
  • Actavis elizabeth llc
  • Apotex inc etobicoke site
  • Caraco pharmaceutical laboratories ltd
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories
Packagers
  • Aidarex Pharmacuticals LLC
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Blenheim Pharmacal
  • Bryant Ranch Prepack
  • Caraco Pharmaceutical Labs
  • Corepharma LLC
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • Eon Labs
  • GD Searle LLC
  • H.J. Harkins Co. Inc.
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • PD-Rx Pharmaceuticals Inc.
  • Pharmacia Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prescription Dispensing Service Inc.
  • Rebel Distributors Corp.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
Dosage forms
FormRouteStrength
TabletOral600 mg
TabletOral600 mg/1
Tablet, film coatedOral600 mg/1
Prices
Unit descriptionCostUnit
Daypro 600 mg tablet2.98USD tablet
Daypro 600 mg caplet2.87USD caplet
Oxaprozin 600 mg tablet1.54USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6030643No1997-05-162017-05-16Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)158-159 °CNot Available
water solubilityInsolubleNot Available
logP4.19HANSCH,C ET AL. (1995)
pKa4.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0325 mg/mLALOGPS
logP3.33ALOGPS
logP3.46ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)4.95ChemAxon
pKa (Strongest Basic)-0.59ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.33 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity81.88 m3·mol-1ChemAxon
Polarizability31.69 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9512
Caco-2 permeable-0.5255
P-glycoprotein substrateNon-substrate0.7938
P-glycoprotein inhibitor INon-inhibitor0.8801
P-glycoprotein inhibitor IINon-inhibitor0.9047
Renal organic cation transporterNon-inhibitor0.8467
CYP450 2C9 substrateNon-substrate0.7623
CYP450 2D6 substrateNon-substrate0.8163
CYP450 3A4 substrateNon-substrate0.5781
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9327
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.93
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6313
Ames testNon AMES toxic0.9191
CarcinogenicityNon-carcinogens0.9364
BiodegradationReady biodegradable0.6095
Rat acute toxicity1.8484 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9906
hERG inhibition (predictor II)Non-inhibitor0.9123
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0090000000-a5f8be833748a4bcb3f8
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0190000000-f93564dbf72195f07577
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0900000000-f1a9a64c5d1e03f85299
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0900000000-17067c043f8330e87007
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-2900000000-0bbeccadc1d2ba259240
MS/MS Spectrum - , positiveLC-MS/MSsplash10-002f-0290000000-ac0cf9f1a6852adb199f

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenyl-1,3-oxazoles. These are aromatic heterocyclic compounds containing a 1,3-oxazole substituted at one or more positions by a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Oxazoles
Direct Parent
Phenyl-1,3-oxazoles
Alternative Parents
2,4,5-trisubstituted oxazoles / Benzene and substituted derivatives / Heteroaromatic compounds / Oxacyclic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides
show 2 more
Substituents
Phenyl-1,3-oxazole / 2,4,5-trisubstituted 1,3-oxazole / Monocyclic benzene moiety / Benzenoid / Heteroaromatic compound / Carboxylic acid derivative / Carboxylic acid / Monocarboxylic acid or derivatives / Azacycle / Oxacycle
show 9 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
1,3-oxazoles, monocarboxylic acid (CHEBI:7822)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Kawai S: Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration. Inflamm Res. 1998 Oct;47 Suppl 2:S102-6. [PubMed:9831331]
  2. Kean WF: Oxaprozin: kinetic and dynamic profile in the treatment of pain. Curr Med Res Opin. 2004 Aug;20(8):1275-7. [PubMed:15324530]
  3. Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. [PubMed:19952416]
  4. Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F: Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157(2):294-306. doi: 10.1111/j.1476-5381.2009.00162.x. Epub 2009 Mar 26. [PubMed:19338579]
  5. Yood MU, Watkins E, Wells K, Kucera G, Johnson CC: The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):852-60. [PubMed:17024689]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Yood MU, Watkins E, Wells K, Kucera G, Johnson CC: The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):852-60. [PubMed:17024689]
  2. Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T, Mizushima Y: Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol. 1998 Apr 17;347(1):87-94. [PubMed:9650852]
  3. Kawai S: Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration. Inflamm Res. 1998 Oct;47 Suppl 2:S102-6. [PubMed:9831331]
  4. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S: Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther. 2002 Jul;302(1):18-25. [PubMed:12065695]
  5. Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. [PubMed:19952416]
  6. Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F: Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157(2):294-306. doi: 10.1111/j.1476-5381.2009.00162.x. Epub 2009 Mar 26. [PubMed:19338579]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on June 16, 2018 22:10